Malaria's next threat: drug-resistant parasites spread even after treatment
NCT ID NCT06347471
First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 4 times
Summary
This study looked at whether malaria parasites that are resistant to artemisinin drugs spread more easily after standard treatment. Researchers treated 160 people in Uganda who had malaria with either artemether-lumefantrine or dihydroartemisinin-piperaquine. They then used mosquito feeding tests to measure how many mosquitoes got infected before, during, and after treatment. The goal was to see if resistant parasites are more likely to be transmitted than non-resistant ones.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Artemether-lumefantrine (Coartem) and dihydroartemisinin-piperaquine (Eurartesim)
- What this could lead to
- If successful, this could help public health officials understand how drug-resistant malaria spreads and guide strategies to contain it.
- What could go wrong
- This is a small, completed observational study (160 participants) in one region, so results may not apply broadly. It measures transmission in the lab, not real-world spread.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALCIPARUM; MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dr. Ambrosoli Memorial Hospital
Kalongo, Agago District, Uganda
-
Patongo Health Facility IV
Patongo, Agago District, Uganda
More trials for these conditions
Other studies related to the condition(s) this trial covers.